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Abstract: Fucus vesiculosus L., known as bladderwrack, belongs to the brown seaweeds, which are
widely distributed throughout northern Russia, Atlantic shores of Europe, the Baltic Sea, Greenland,
the Azores, the Canary Islands, and shores of the Pacific Ocean. Fucoidan is a major fucose-rich
sulfated polysaccharide found in Fucus (F.) vesiculosus. The pharmacokinetic profiling of active
compounds is essential for drug development and approval. The aim of the study was to evaluate the
pharmacokinetics and tissue distribution of fucoidan in rats after a single-dose oral administration.
Fucoidan was isolated from F. vesiculosus. The method of measuring anti-activated factor X (anti-Xa)
activity by amidolytic assay was used to analyze the plasma and tissue concentrations of fucoidan.
The tissue distribution of fucoidan after intragastric administration to the rats was characterized,
and it exhibited considerable heterogeneity. Fucoidan preferentially accumulates in the kidneys
(AUC0–t = 10.74 µg·h/g; Cmax = 1.23 µg/g after 5 h), spleen (AUC0–t = 6.89 µg·h/g; Cmax = 0.78 µg/g
after 3 h), and liver (AUC0–t = 3.26 µg·h/g; Cmax = 0.53 µg/g after 2 h) and shows a relatively long
absorption time and extended circulation in the blood, with a mean residence time (MRT) = 6.79 h.
The outcome of this study provides additional scientific data for traditional use of fucoidan-containing
plants and offers tangible support for the continued development of new effective pharmaceuticals
using fucoidan.
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1. Introduction
Fucus vesiculosus L., known as bladderwrack, belongs to the brown seaweeds, which are
widely distributed throughout northern Russia, Atlantic shores of Europe, the Baltic Sea, Greenland,
the Azores, the Canary Islands, and shores of the Pacific Ocean. Many species of brown seaweeds have
been used in food products and also documented as being used in traditional medicine [1,2]. Some
Western herbal products containing F. vesiculosus are known to be used topically for the treatment of
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sore knees [3], healing wounds [4], and also as herbal teas for their laxative or weight control effects [5].
F. vesiculosus has been reported for the treatment of the uterus and ovaries in the Caribbean islands [6].
Fucoidan is a cell-wall fucose-rich sulfated polysaccharide that is mainly found in brown
algae of the class Phaeophyceae [7]. Fucoidan has been used as an anticancer drug in traditional
Chinese medicine [8]. It shows a wide range of biological activities including anticoagulant,
anti-inflammatory [9], antidiabetic [10], procoagulant [11], anticancer [12], and antiviral activities [13].
Currently, fucoidan is not approved for medical applications. However, it is considered a promising
drug candidate due to its low toxicity [14], good biocompatibility [15], and encouraging results in
preclinical and sporadic early-stage clinical trials [16,17].
The pharmacokinetic profiling of active molecules is essential for the drug development process.
Reliable analytical methods are required for the understanding of the pharmacokinetics of fucoidan.
A limited number of assays for the quantification of fucoidan in plasma or biological samples have been
reported. A competitive ELISA was developed and used for the detection of Undaria (U.) pinnatifida
fucoidan in plasma after oral ingestion of the compound by human volunteers [18]. Later, a more
sensitive sandwich ELISA was described for Cladosiphon okanuramus fucoidan in human serum and
urine [19]. Methods using electrochemical detection [20] and direct fluorescent assay of brown
algae-derived fucoidans in human plasma with the commercially available Heparin Red Kit [21] have
been reported.
Heparins display certain structural similarities to fucoidans with respect to their polysaccharide
nature and high negative charge density due to sulfation. A positive correlation between biological
activity and concentration in plasma was demonstrated for heparin [22,23]. A recent report suggested
that plasma antiactivated factor X (anti-Xa) activity must be tested in order to achieve an effective
anticoagulant level in patients receiving anticoagulant therapy with enoxaparin [24]. An anti-Xa
chromogenic assay was validated for the quantification of enoxaparin in human plasma [25].
Some authors have proposed that fucoidan shows heparin-like actions such as prolonging
activated partial thromboplastin time via anti-Xa and anti-IIa activity [16]. However, we have found no
reports regarding the tissue distribution of fucoidan after oral administration. In our study, a method
for detecting fucoidan based on its anti-Xa activity was established in rats. The method was used to
investigate the pharmacokinetic and tissue distribution of fucoidan isolated from F. vesiculosus after a
single-dose oral administration.
2. Results
2.1. Chemical Composition of Fucoidan
The average molecular mass of the purified fucoidan was estimated to be 735 kDa.
The polysaccharide contained 79.5% neutral carbohydrates, 27.0% sulfate residues, and 0.7% uronic
acid. According to the HPLC analysis, the fucoidan contained fucose, glucose, galactose, xylose,
mannose, and arabinose at a molar ratio of 1.0:0.16:0.05:0.09:0.03:0.03, respectively. The major
monosaccharide was fucose (73.5 mol%), followed by glucose (11.8 mol%) and xylose (6.6 mol%).
Other monosaccharides were present at minor concentrations.
2.2. Method Validation
The International Conference on Harmonization (ICH) guidelines on the validation of analytical
methods were used [26,27]. A comparison of the UV spectra of the reaction products showed that
the components in blood plasma do not affect the spectra of the reaction products of the heparin
kit. The calibration curve for fucoidan was linear over a concentration range of 0.027–0.217 µg/mL.
The fucoidan concentration was calculated according to the equation: y = 0.1234x + 0.0197; (R2 = 0.992),
where y is the concentration (µg/mL) and x is the anti-Xa activity from which the endogenous level
was subtracted. The validation data for the method of determining fucoidan concentration in blood
plasma are presented in Table 1.
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Table 1. The validation data for the method of determining fucoidan in blood plasma.
Parameter Range
Accuracy, %
ULOQ (0.217 µg/mL) 0.64–3.10
Middle-quality control (0.108 µg/mL) 1.12–4.20
Low-quality control (0.054 µg/mL) 5.5–12.0
LLOQ (0.027 µg/mL) 3.0–7.1
Intraday//Interday precision (RSD), %
ULOQ (0.217 µg/mL) 0.8–2.5//2.3
Middle-quality control (0.108 µg/mL) 4.0–4.5//4.6
Low-quality control (0.054 µg/mL) 6.5–8.1//8.6
LLOQ (0.027 µg/mL) 0.7–6.2//11.6
LOD, µg/mL 0.01
ULOQ, upper limit of quantification; LLOQ, lower limit of quantification; LOD, limit of detection.
2.3. Pharmacokinetic and Tissue Distribution
No such clinical signs of toxicity as mortality, aggression, changes in locomotor activity, tremor,
convulsions, pain, or touch response were observed in the treated group. Figure 1 shows the mean
plasma and tissues profiles of fucoidan after intragastric administration to the rats.
The highest concentration of fucoidan (Cmax = 1.23 µg/g) was found in the kidneys, while the
lowest level was found in the plasma (Cmax = 0.125 µg/mL, Figure 1). The pharmacokinetic parameters
of fucoidan distribution in plasma, kidneys, spleen, liver, striated muscle, and omentum are presented
in Table 2. The values of tissue availability (ft) provided evidence about the highest concentration of
fucoidan in the kidneys.
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Table 2. Pharmacokinetic parameters of fucoidan in plasma and tissues after intragastric administration
to rats.
Sample
Parameters
AUC0–t (µg·h/g) * MRT (h) T1/2 (h) ft
Plasma 0.99 ± 0.27 6.79 ± 1.63 3.44 ± 1.70 -
Liver 3.26 ± 1.54 9.25 ± 3.78 6.44 ± 3.57 3.29
Kidneys 10.74 ± 5.15 12.39 ± 4.26 7.26 ± 3.09 10.85
Spleen 6.89 ± 2.87 14.57 ± 6.51 9.32 ± 5.12 6.96
Striated muscle 1.49 ± 0.22 5.43 ± 0.82 2.36 ± 0.84 1.50
Omentum 1.10 ± 0.22 7.78 ± 0.93 4.30 ± 0.79 1.11
* AUC0–t (µg·h/mL) for plasma. AUC0–t, the area under the curve; MRT, mean residence time; T1/2, apparent
half-life of elimination; ft, the tissue availability. The results are expressed as the mean ± SD (n = 5).
3. iscussion
The phar acokinetics and tissue distribution are crucial in understanding biological activity.
The icrodeter ination of fucoidan distribution is one of the key proble s in its phar acokinetic
studies. atural polysaccharides contain very fe chro ophores and reactive groups. The analysis
of fucoidan in biological sa ples is co plicated because of its etabolites and its lo concentration
in vivo after oral ad inistration. It has been proposed that the various biological effects of fucoidan
originate in the physiological reactions in the gastrointestinal tract and that fucoidan is scarcely
absorbed into the blood [19]. e believe that this opinion has been formed because there have been no
sensitive methods to detect fucoidan in biological samples.
In our study, an anti-Xa activity assay for the detection of fucoidan as successful in the
characterization of the phar acokinetics and tissue distribution of fucoidan in plas a and tissues.
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The results of this study demonstrate that fucoidan at the dose of 100 mg/kg with molecular
weight of 735 kDa was detected in rat plasma 30 min after the intragastric administration.
The Cmax = 0.125 µg/mL was observed at 4 h (Figure 1). The highest concentration of fucoidan (66 kDa)
after a single oral administration of 1 g in human volunteers (63 ng/mL) was observed by ELISA in
serum at 6 or 9 h [19]. The doses of fucoidan in our study and that of Tokita et al. [19] were similar,
taking into account the human equivalent dose (HED). However, the fucoidan concentration in the
human blood was about two times lower than the level obtained by us. Apparently, this finding results
from a faster rate of metabolism in rats and the different source of fucoidan and its molecular weight.
An ELISA competitive-based assay was used for the analysis of fucoidan in plasma from healthy
volunteers who for 12 days, ingested 3 g/day of extracts from U. pinnatifida containing 10% or 75%
of fucoidan (713 kDa) [18]. The plasma concentration in samples from volunteers who received 10%
or 75% fucoidan was 4.00 or 12.99 mg/L, respectively, while the highest concentration after 12 days
was 5.08 or 15.75 mg/L, respectively. The concentration of fucoidan in our study was much lower
than the levels obtained by Irhimeh et al. [18]. This difference may be explained by the cumulative
effect and higher doses of fucoidan used in the human trial, differences in metabolism, and analytical
methods used. Recently, Zhang et al. [28] reported a HPLC method with postcolumn fluorescence
derivatization for the analysis of fucoidan and its metabolites in rabbits. The limit of detection and limit
of quantification were determined to be 0.125 µg/mL and 0.5 µg/mL, respectively. Using this method,
it was shown that low-molecular-weight (7.1 kDa) fucoidan (50 mg/kg of body weight, intravenous
administration) was rapidly absorbed in rabbits. The highest concentration of 110.53 µg/mL was
observed at 5 min. The concentration–time curve was biexponential, while the half-life times were
T1/2α = 11.24 ± 2.93 min and T1/2β = 98.20 ± 25.78 min. No drug was detected after 6 h. However,
the sensitivity of the method was too low for the qualitative analysis of fucoidan after intragastric
administration to rabbits (200 mg/kg of body weight). The drug was detected only approximately
2 h after administration, but no concentration was provided in the manuscript. We suppose that the
sensitivity of that method was lower than our ELISA method. However, the pretreatment of biological
samples was also different and may play a critical role as well. Intestinal absorption of fucoidan
(28.8 kDa) was studied in rats fed 2% fucoidan chow for one or two weeks. Serum fucoidan reached a
concentration of 2.7 ng/mL after two weeks. According to histological data, the epithelial cells of the
jejunum were stained positively for fucoidan [29].
The low-molecular-weight fucoidan was quite quickly eliminated from the blood after intravenous
injection in rabbits (MRT = 109 min) and was not detected in the blood 2 h after intragastric
administration [28]. Our results imply that intragastric administration of high-molecular-weight
fucoidan gave the prolonged MRT value of 6.79 ± 1.63 h and provided evidence about the relatively
low absorption and long circulation of fucoidan in the blood.
Furthermore, our study is the first study in which the tissue distribution of fucoidan in rats after a
single-dose oral administration has been studied. We found that fucoidan preferentially accumulates
in the organs with the greatest “filtering” function, namely the kidneys, spleen, and liver (Table 2).
In our study, fucoidan was mainly concentrated in the kidney. Recently, the renoprotective role of
fucoidan was confirmed in animal studies using models of kidney injury [30,31]. This finding agrees
with our evidence of the relatively long MRT of 13.39 h in the kidney.
High-molecular-weight fucoidan enhances the viability and prevents the death of spleen cells [32].
Interestingly, in our experiments, the most prolonged MRT of 14.57 h was observed for fucoidan in the
spleen (Table 2). Administration of fucoidan reduced CCl4-induced acute and chronic liver failure in
rats [33]. Our findings regarding the liver distribution of fucoidan support and could explain this effect
as well. Chen et al. [34] have reported that fucoidan supplementation improves exercise performance
and exhibit antifatigue actions in mice. In our study, fucoidan was determined in the muscles for the
first time. The AUC of fucoidan was relatively low; however, its antifatigue function may be associated
with its MRT of 5.43 h.
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4. Materials and Methods
4.1. Materials
The brown seaweed F. vesiculosus was randomly collected from the littoral of the Barents Sea
(Dalnie Zelentsy, Murmansk region, Russia) in August 2015. Seaweed was washed with fresh water,
frozen, and stored at −18 ◦C before being analyzed. The identification was performed by Dr. E.D.
Obluchinskaya. The voucher specimen (No. 8.2015, V.D.Z.) was deposited in the Collection of the
Algology Laboratory, Murmansk Marine Biology Institute. Analytical grade chemicals and solvents
for extraction and analysis were purchased from local chemical suppliers. Deionized water, filtered
through a 0.22-µm filter, was used to reconstitute the calibrators, factor Xa, chromogenic substrate,
and antithrombin.
4.2. Extraction Procedures
Fucoidan was isolated as earlier shown [35], with some modifications. Briefly, a frozen seaweed
sample (100 g) was ground and extracted with 100 mL of a mixture of methylene chloride/ethanol
(94.2:5.8, v/v). After filtration, the residue was extracted in an ultrasound bath (Branson 3510DTH,
Branson Ultrasonics Corp., Danbury, CT, USA) with a 5% aqueous solution of ethanol at 40 ◦C for 4 h
at pH 3–4. The liquid fraction was isolated by centrifugation (10,000× g for 15 min) using Sigma 2K15
(Mason Technology, Dublin, Ireland). After centrifugation, the crude fucoidan was dialyzed through a
tangential membrane filter and freeze-dried. The yield was 4.9% by mass.
4.3. Analysis of Fucoidan Composition
For the analysis of the molecular weight distribution, fucoidan was dissolved in highly purified
H2O, filtered through a membrane filter (0.45 µm), and separated over Shodex Asahipak (Kanagawa,
Japan) GS-520 HQ and GS-620 HQ (7.5× 300 mm) columns. The elution was done by H2O (0.5 mL/min)
at 60 ◦C. Standard pullulans with MWs 6.2–740 kDa (Polymer Laboratories, Houston, TX, USA)
were used for calibration of columns. The molecular mass distribution of fucoidan was assessed by
normalizing the peak areas [36]. The total neutral carbohydrate of fucoidan was analyzed by the
phenol-sulfuric acid method [37] using L-fucose as a reference. The BaCl2-gelatin method was used for
sulfate residue determination [38], using Na2SO4 as a standard. Uronic acid content was analyzed by
the carbazole reaction [39], using D-glucuronic acid as a reference.
The monosaccharides were analyzed by high-performance liquid chromatography (Shimadzu
HPLC system, Kyoto, Japan) according to a previous method [40].
4.4. Animals
Male rats (n = 50) were obtained from Rapplovo animal house (St. Petersburg, Russia). The animals
were kept under standard conditions with a 12-h light–dark cycle, at ambient temperature (22 ± 2 ◦C),
and relative humidity of 60 ± 10%. They had free access to food (Standard diet: Volosovo, Russia) and
water ad libitum. Rats (n = 5 per time point) were fasted overnight before the experiment. In human
experiments, fucoidan was safe at the oral dose of 1 g/day [3,19]. It was shown in our preliminary
study that fucoidan was not toxic after intragastric administration to rats at doses up to 2000 mg/kg.
The fucoidan dose was converted from a human equivalent dose (HED) by the following formula
recommended by the U.S. Food and Drug Administration [41]. The HED (human weight of 60 kg)
for 1 (g)/60 (kg) = 0.0167 × 6.2 = a rat dose of 0.10354 g/kg or ~100 mg/kg. The rationality of this
dose selection is supported by previous reports. Renoprotective activity of fucoidan was observed
at the dose of 100–200 mg/kg/day in Wistar rats [30]. A dose of 100 mg/kg/day was effective in
streptozotocin-induced diabetic rats [10]. Fucoidan (100 mg/kg) in starch slime was administered to
rats intragastrically by gavage. After administration, the rats were euthanized in a CO2 chamber and
the blood was collected in sodium citrate tubes by cardiac puncture at different time points (30 min, 1,
2, 3, 4, 5, 6, 8, 12, and 24 h). The blood was centrifuged at 3000× g for 15 min at 4 ◦C, then the plasma
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was collected and stored at −20 ◦C. The organs were removed by surgical resection. The organs with
different vascularity were selected according to the recommendations [42].
Each organ sample was precisely weighed and homogenized (Polytron PT-MR 1600E, Kinematica
AG, Lucerne, Switzerland) in 0.15 µM Tris-HCl buffer (pH 8.4). After vortex-mixing and centrifugation
for 15 min at 3000× g (EBA21 tabletop centrifuge, Hettich, Westphalia, Germany), the upper phase
was collected and used for an amidolytic assay.
Experiments were performed according to the directive 267, “Regarding the statement of
regulation of laboratory practice of the Ministry of Health of the Russia” (2003) and the EEC Directive
of 1986 (86/609/EEC), and were approved by the Ethical Commission of the St. Petersburg Institute of
Pharmacy (Leningrad Region, Vsevolozhsky District, Kuzmolovo P 245, Russia).
4.5. Analysis of Anti-Xa Activity
The anti-Xa activity was analyzed by amidolytic assay using a ReaChrom Heparin kit (Renam,
Russia). The reaction sequence underpinning the anti-Xa assay includes three steps (adopted from [25]):
(1) fucoidan + antitrombine III (ATIII)→ ATIII–fucoidan
(2) ATIII–fucoidan + Xa→ ATIII–fucoidan–Xa + Xafree
(3) Xafree + substrate–pNA→ peptide + pNA
Steps (1) and (2) occur in a plasma/organ sample. Step (3) occurs when the substrate is added to
the plasma/organ sample in the laboratory test. Factor Xa is not inactivated by the fucoidan and is free
to react with the added substrate, resulting in the formation of p-nitroanilide (pNA). The appearance
of pNA, determined spectrophotometrically, is inversely proportional to the concentration of fucoidan
in a plasma/organ sample.
The test solutions were prepared by mixing 20 µL of an organ homogenate or calibration standards
of fucoidan or a calibrator solution with an appropriate volume of 0.15 µM Tris-HCl buffer (pH 8.4) to fit
with concentration in a linear range, while plasma samples were used without dilution. The appropriate
dilution coefficient was used for calculations.
The reaction mixture consisting of 20 µL of the test solution, 20 µL of an ATIII solution (activity
of 0.2 U/mL), and 80 µL of 0.15 µM Tris-HCl buffer was incubated (ST-3L shaker, Elmi, Latvia) at
37 ◦C for 2 min. Then, 40 µL of aqueous solution of factor Xa (activity of 2 U/mL) was added for the
initiation of reaction. After incubation at 37 ◦C for 5 min, 40 µL of a synthetic chromogenic substrate
(2 mM) was added. Five minutes later, the reaction was stopped by adding of 80 µL of 50% acetic acid.
A control contained 60 µL of buffer instead of the test solution and factor Xa. The optical density of free
pNA was determined at 405 nm using a microplate spectrophotometer (X-Mark; Bio-Rad, Hercules,
CA, USA). The endogenous level of products reacted with the heparin kit was subtracted at each time
point in each sample.
4.6. Pharmacokinetic and Statistical Analysis
The pharmacokinetic calculations for fucoidan in organs and plasma were performed with the
Excel add-in program PK Solver. The parameters were calculated from the concentration-time data
using a noncompartmental pharmacokinetic model as described previously [43]. The results are
expressed as the mean ± standard deviation (n = 5 for each time point). Statistica ver. 6.0 software
(Statsoft, Palo Alto, CA, USA) was used for analysis.
5. Conclusions
This report is the first study of fucoidan to reveal its important fundamental pharmacokinetic
properties and tissue distribution after oral administration to rats. The outcomes of this study provide
additional scientific data for the traditional use of fucoidan-containing plants and offers tangible
support for the continued development of new effective pharmaceuticals containing fucoidan.
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